Trial Profile
Post-authorization Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration Among Patients Treated With Empagliflozin or DPP-4 Inhibitors in Saudi Arabia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 29 Jan 2021 Status changed from active, no longer recruiting to completed.
- 17 Jul 2020 Planned primary completion date changed from 30 Jun 2020 to 31 Dec 2020.
- 31 Jan 2020 Status changed from recruiting to active, no longer recruiting.